Contact

Our portfolio

Rsouth Antibodies

Rsouth Antibodies has developed a therapeutic antibody for Respiratory Syncytial Virus (RSV) that has been licensed to MedImmune (now AstraZeneca). AstraZeneca has finalized clinical validation and obtained regulatory approval for this antibody that is now marketed by Sanofi as Nirsevimab for prevention of RSV in infants. Since RSV infection have been on the rise again since 2022, many lives have already been saved by treatment with Nirsevimab.

  • Institute: Amsterdam UMC
Industry: Infectious Disease, Therapeutics
  • Founding year: 2018
Visit website

Want to get in contact about Rsouth Antibodies?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Glass Medical AI
Stratifying patients for oncology trials with explainable AI on pathology data.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Plantics
Reducing plastic waste and lowering CO2 emissions.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Glass Medical AI
Stratifying patients for oncology trials with explainable AI on pathology data.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Plantics
Reducing plastic waste and lowering CO2 emissions.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Explore full AAV portfolio
Contact